Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition-Reference-Cited by-同舟云学术

Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition

Published:2022-07-14 Issue:2 Volume:387 Page:160-166
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Notaro Rosario¹^ORCID,Luzzatto Lucio¹^ORCID

Affiliation:

1. From Istituto per lo Studio, la Prevenzione e la Rete Oncologica (R.N.), and the University of Florence (L.L.) — both in Florence, Italy; and the Department of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania (L.L.).

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMra2201664

Reference51 articles.

1. Paroxysmal nocturnal haemoglobinuria

2. Paroxysmal Nocturnal Hemoglobinuria: Evidence for Monoclonal Origin of Abnormal Red Cells

3. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria

4. Biosynthesis, Remodelling and Functions of Mammalian GPI-anchored Proteins: Recent Progress

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement‐targeted therapeutics: Are we there yet, or just getting started?;European Journal of Immunology;2024-09-12

2. Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria;Expert Review of Clinical Pharmacology;2024-09-11

3. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31

4. The complement model disease paroxysmal nocturnal hemoglobinuria;European Journal of Immunology;2024-08-05

5. CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation;Blood Advances;2024-08-02